Didier Wion

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1026443/publications.pdf

Version: 2024-02-01

94381 98753 4,877 115 37 67 citations h-index g-index papers 118 118 118 5341 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	3D two-photon polymerization of smart cell gelatin $\hat{a} \in \text{``collagen matrixes with incorporated}$ ruthenium complexes for the monitoring of local oxygen tensions. Acta Biomaterialia, 2021, 130, 172-182.	4.1	6
2	Randomized clinical trials of oral vitamin D supplementation in need of a paradigm change: The vitamin D autacoid paradigm. Medical Hypotheses, 2020, 134, 109417.	0.8	1
3	Early Prophylactic Hypothermia for Patients With Severe Traumatic Injury: Premature to Close the Case. Frontiers in Neurology, 2019, 10, 344.	1.1	2
4	Biomarkers of aging associated with past treatments in breast cancer survivors: when therapy-induced pathways turn out to be potential therapeutic targets. Npj Breast Cancer, 2018, 4, 4.	2.3	2
5	Letter to the Editor: "Decreased Serum 25-Hydroxyvitamin D in Aging Male Mice Is Associated With Reduced Hepatic Cyp2r1 Abundance― Endocrinology, 2018, 159, 3563-3564.	1.4	O
6	The Temporal Relationship Between Alzheimer's Disease and Depressive Symptoms: Variable Matters. American Journal of Psychiatry, 2018, 175, 793-793.	4.0	2
7	Inflammation and Inflammatory Diseases: How Our Language Influences Our Therapeutic Paradigms. BioEssays, 2018, 40, e1800103.	1.2	1
8	Reprogramming glioma cell cultures with retinoic acid: Additional arguments for reappraising the potential of retinoic acid in the context of personalized glioma therapy. Glioma (Mumbai, India), 2018, 1, 66.	0.0	6
9	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumor Biology, 2017, 39, 101042831769979.	0.8	45
10	Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia. Journal of Neuro-Oncology, 2017, 133, 447-454.	1.4	17
11	Vitamin D and mental health: optimizing in the midst of the complexity. Acta Psychiatrica Scandinavica, 2017, 136, 228-229.	2.2	1
12	Locoregional Confinement and Major Clinical Benefit of ¹⁸⁸ Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma. Theranostics, 2017, 7, 4517-4536.	4.6	46
13	Glioma Recurrence following Surgery: Peritumoral or Perilesional?. Frontiers in Neurology, 2016, 7, 52.	1.1	5
14	Design of Hyaluronic Acid Hydrogels to Promote Neurite Outgrowth in Three Dimensions. ACS Applied Materials & Samp; Interfaces, 2016, 8, 25051-25059.	4.0	44
15	Extent of Resection and Survival in Glioblastoma Multiforme. JAMA Oncology, 2016, 2, 1509.	3.4	2
16	Glioma resection and tumor recurrence: back to Semmelweis. Neuro-Oncology, 2016, 18, 1688-1689.	0.6	12
17	RE: Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. Journal of the National Cancer Institute, 2016, 108, .	3.0	1
18	The brain tissue response to surgical injury and its possible contribution to glioma recurrence. Journal of Neuro-Oncology, 2016, 128, 1-8.	1.4	63

#	Article	IF	Citations
19	Investigating the relationship between vitamin D and cancer requires dosing the bioavailable nonhydroxylated vitamin D storage in cancer tissues. Cancer, 2015, 121, 3362-3363.	2.0	6
20	Expression of CYP2R1 and VDR in human brain pericytes. NeuroReport, 2015, 26, 245-248.	0.6	23
21	Cancer research in need of a scientific revolution: Using †paradigm shift' as a method of investigation. Journal of Biosciences, 2015, 40, 657-666.	0.5	6
22	Video lensfree microscopy of 2D and 3D culture of cells. , 2014, , .		4
23	Imaging and histological characterization of a human brain xenograft in pig: The first induced glioma model in a large animal. Journal of Neuroscience Methods, 2014, 221, 159-165.	1.3	21
24	Additional Clues for a Protective Role of Vitamin D in Neurodegenerative Diseases: 1,25-Dihydroxyvitamin D3 Triggers an Anti-Inflammatory Response in Brain Pericytes. Journal of Alzheimer's Disease, 2014, 42, 789-799.	1.2	55
25	Generation of brain cancer stem cells: The dark side of brain pericytes?. Neuroscience Research, 2014, 85, 69.	1.0	0
26	Brain mesenchymal stem cells: The other stem cells of the brain?. World Journal of Stem Cells, 2014, 6, 134.	1.3	60
27	Hypoxia-induced expression of VE-cadherin and filamin B in glioma cell cultures and pseudopalisade structures. Journal of Neuro-Oncology, 2013, 113, 239-249.	1.4	18
28	Translation of the ecological trap concept to glioma therapy: the cancer cell trap concept. Future Oncology, 2013, 9, 817-824.	1.1	21
29	Synergistic effect of cisplatin and synchrotron irradiation on F98 gliomas growing in nude mice. Journal of Synchrotron Radiation, 2013, 20, 777-784.	1.0	8
30	The Transcriptomic Response of Mixed Neuron-Glial Cell Cultures to 1,25-Dihydroxyvitamin D3 Includes Genes Limiting the Progression of Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2013, 35, 553-564.	1.2	28
31	Cortical dysplasia: a possible substrate for brain tumors. Future Oncology, 2012, 8, 251-258.	1.1	1
32	Angiogenesis and the tumor space-time continuum. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E914-E914.	3.3	4
33	Biodiversity as a barrier to glioma cell invasion. Medical Hypotheses, 2012, 78, 459-461.	0.8	3
34	Stem Cell Culture: Optimizing Amidst the Complexity. Stem Cells and Cancer Stem Cells, 2012, , 3-12.	0.1	1
35	In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expression. International Journal of Oncology, 2011, 40, 1220-9.	1.4	7
36	Existence of tumor-derived endothelial cells suggests an additional role for endothelial-to-mesenchymal transition in tumor progression. International Journal of Cancer, 2011, 128, 1502-1503.	2.3	10

#	Article	IF	Citations
37	The heterogeneity of meningioma revealed by multiparameter analysis: infiltrative and non-infiltrative clinical phenotypes. International Journal of Oncology, 2011, 38, 1287-97.	1.4	4
38	MicroRNA and Target Protein Patterns Reveal Physiopathological Features of Glioma Subtypes. PLoS ONE, 2011, 6, e20600.	1.1	121
39	Optimizing stem cell culture. Journal of Cellular Biochemistry, 2010, 111, 801-807.	1.2	67
40	Increased Phosphorylation of Vimentin in Noninfiltrative Meningiomas. PLoS ONE, 2010, 5, e9238.	1.1	46
41	Characterisation of normal and cancer stem cells: One experimental paradigm for two kinds of stem cells. BioEssays, 2009, 31, 993-1001.	1.2	11
42	Cancer stem cells: Beyond Koch's postulates. Cancer Letters, 2009, 278, 3-8.	3.2	22
43	PO2 Matters in Stem Cell Culture. Cell Stem Cell, 2009, 5, 242-243.	5.2	49
44	Abstract A60: Targeting brain tumor stem cells. , 2009, , .		0
45	Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Letters, 2007, 258, 286-290.	3.2	164
46	Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Letters, 2007, 581, 1435-1440.	1.3	39
47	Effects of Hoechst 33342 on C2C12 and PC12 cell differentiation. FEBS Letters, 2007, 581, 3076-3080.	1.3	28
48	Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase. FEBS Letters, 2006, 580, 3179-3184.	1.3	65
49	N6-methyl-adenine: an epigenetic signal for DNA–protein interactions. Nature Reviews Microbiology, 2006, 4, 183-192.	13.6	485
50	N6-methyladenine: the other methylated base of DNA. BioEssays, 2006, 28, 309-315.	1.2	227
51	Cancer Stem Cells. New England Journal of Medicine, 2006, 355, 2703-2703.	13.9	17
52	Glioma, Melatonin, and Radiotherapy. Cancer Research, 2006, 66, 6457-6457.	0.4	5
53	Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. British Journal of Cancer, 2006, 94, 1066-1070.	2.9	34
54	Should We Control the Pineal Status of Patients following Brain Radiotherapy?. Journal of Neuro-Oncology, 2005, 74, 335-335.	1.4	3

#	Article	IF	CITATIONS
55	Vitamin D, A Neuroactive Hormone: From Brain Development to Pathological Disorders. , 2005, , 1779-1789.		1
56	RNA mutagenesis and sporadic prion diseases. Journal of Theoretical Biology, 2004, 230, 271-274.	0.8	5
57	N6-Methyldeoxyadenosine, a nucleoside commonly found in prokaryotes, induces C2C12 myogenic differentiation. Biochemical and Biophysical Research Communications, 2004, 314, 476-482.	1.0	18
58	Development of gliomas: potential role of asymmetrical cell division of neural stem cells. Lancet Oncology, The, 2004, 5, 511-514.	5.1	68
59	Induction of neurite outgrowth in PC12 cells by the bacterial nucleoside N6-methyldeoxyadenosine is mediated through adenosine A2a receptors and via cAMP and MAPK signaling pathways. Biochemical and Biophysical Research Communications, 2003, 304, 795-800.	1.0	34
60	What is, mutatis mutandis, the sequence of plasmid DNAs used in gene therapy?. Medical Hypotheses, 2003, 60, 711-715.	0.8	1
61	New clues about vitamin D functions in the nervous system. Trends in Endocrinology and Metabolism, 2002, 13, 100-105.	3.1	759
62	p53 Status and Gene Transfer Experiments Using CMV Enhancer/Promoter. Biochemical and Biophysical Research Communications, 2001, 280, 45-47.	1.0	8
63	The Bacterial Nucleoside N6-Methyldeoxyadenosine Induces the Differentiation of Mammalian Tumor Cells. Biochemical and Biophysical Research Communications, 2001, 285, 800-805.	1.0	16
64	Programmed Cell Death or Cell Death Programme? That is the Question. Journal of Theoretical Biology, 2001, 208, 385-386.	0.8	16
65	Quality control of plasmid preparations. Nature Biotechnology, 2001, 19, 715-715.	9.4	4
66	Bacterial Hotspots and Cancer Gene Therapy. Journal of the National Cancer Institute, 2000, 92, 162-162.	3.0	12
67	Bacterial DNA Methylation and Gene Transfer Efficiency. Biochemical and Biophysical Research Communications, 2000, 276, 1261-1264.	1.0	15
68	An enzymatic procedure for the purification of DNA restriction fragments without gel electrophoresis and ethidium bromide staining. Comptes Rendus De L'Académie Des Sciences Série 3, Sciences De La Vie, 2000, 323, 753-756.	0.8	1
69	Brief Report: Muscle Transfection by Electroporation with High-Voltage and Short-Pulse Currents Provides High-Level and Long-Lasting Gene Expression. Human Gene Therapy, 2000, 11, 909-916.	1.4	119
70	La représentation des séquences des ADN plasmidiques utilisés en thérapie génique à l'aide des symboles A, T, G, C est elle satisfaisante ?. Medecine/Sciences, 2000, 16, 295.	0.0	0
71	Vitamin D, a Hormone Involved in the Control of Neuro-Immune Interactions in the Brain. Research and Perspectives in Neurosciences, 2000, , 193-201.	0.4	0
72	Mycoplasmas as gene therapy vectors?. Nature Biotechnology, 1999, 17, 4-4.	9.4	0

#	Article	IF	Citations
73	Are sequences of plasmid DNA used in gene therapy erroneous?. Nature Biotechnology, 1999, 17, 517-517.	9.4	10
74	Mycoplasma: a new potential vector for gene therapy?. Medical Hypotheses, 1999, 52, 605-607.	0.8	2
75	Differentially expressed genes in C6.9 glioma cells during vitamin D-induced cell death program. Cell Death and Differentiation, 1998, 5, 116-125.	5.0	64
76	RLU and studies using the luciferase reporter gene. Nature Biotechnology, 1998, 16, 702-702.	9.4	1
77	Epigenetic control of programmed cell death: inhibition by 5-azacytidine of 1,25-dihydroxyvitamin D3-induced programmed cell death in C6.9 glioma cells. Mechanisms of Ageing and Development, 1998, 101, 153-166.	2.2	12
78	Vitamin D receptor stable transfection restores the susceptibility to 1,25-dihydroxyvitamin D3cytotoxicity in a rat glioma resistant clone. Journal of Neuroscience Research, 1998, 52, 210-219.	1.3	27
79	Noradrenaline inhibits the programmed cell death induced by 1,25-dihydroxyvitamin D3 in glioma. European Journal of Pharmacology, 1997, 319, 365-368.	1.7	13
80	Was the formation of 1,25-dihydroxyvitamin D3 initially a catabolic pathway?. Medical Hypotheses, 1997, 48, 325-329.	0.8	3
81	1,25-Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor. Molecular Brain Research, 1996, 41, 259-268.	2.5	66
82	Regulation of NGF, BDNF and LNGFR gene expression in ROS 17/2.8 cells. Molecular and Cellular Endocrinology, 1996, 116, 149-156.	1.6	19
83	Cytotoxic effects of $1\hat{l}\pm$,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. Cancer Letters, 1996, 100, 3-10.	3.2	40
84	1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. NeuroReport, 1996, 7, 2171-2175.	0.6	182
85	1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. , 1996, 46, 540-550.		45
86	Expression of the nerve growth factor gene is controlled by the microtubule network. Journal of Neuroscience Research, 1995, 41, 462-470.	1.3	13
87	Interactions between second messenger pathways influence NGF synthesis in mouse primary astrocytes. Brain Research, 1995, 672, 128-136.	1.1	23
88	Induction of glioma cell death by 1,25 (OH)2 vitamin D3: Towards an endocrine therapy of brain tumors?. Journal of Neuroscience Research, 1994, 37, 271-277.	1.3	90
89	Synthesis of 1,25-dihydroxyvitamin D3by rat brain macrophages in vitro. Journal of Neuroscience Research, 1994, 38, 214-220.	1.3	106
90	1,25-Dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Molecular Brain Research, 1994, 24, 70-76.	2.5	210

#	Article	IF	Citations
91	A theory that may explain the Hayflick limit — a means to delete one copy of a repeating sequence during each cell cycle in certain human cells such as fibroblasts. Mechanisms of Ageing and Development, 1994, 75, 205-213.	2.2	6
92	Reactive Oxygen Species Influence Nerve Growth Factor Synthesis in Primary Rat Astrocytes. Journal of Neurochemistry, 1994, 62, 2178-2186.	2.1	30
93	Enhancement of the Synthesis and Secretion of Nerve Growth Factor in Primary Cultures of Glial Cells by Proteases: A Possible Involvement of Thrombin. Journal of Neurochemistry, 1993, 60, 858-867.	2.1	76
94	Complex Interactions Among Second Messenger Pathways, Steroid Hormones, and Protooncogenes of the Fos and Jun Families Converge in the Regulation of the Nerve Growth Factor Gene. Journal of Neurochemistry, 1993, 60, 1843-1853.	2.1	38
95	Expression of 25(OH) vitamin D3 24-hydroxylase gene in glial cells. NeuroReport, 1993, 5, 255-257.	0.6	57
96	Alteration in the levels of 1,25-(OH)2D3 and corticosterone found in experimental diabetes reduces nerve growth factor (NGF) gene expression. Life Sciences, 1992, 50, 1769-1772.	2.0	21
97	Activation of nerve growth factor synthesis in primary glial cells by phorbol 12-myristate 13-acetate: role of protein kinase C. Brain Research, 1992, 570, 316-322.	1.1	50
98	Pertussis toxin provides evidence for two independent signalling pathways leading to the activation of the nerve growth factor gene. Journal of Neuroscience Research, 1992, 31, 294-300.	1.3	9
99	Nerve growth factor-induced neuronal differentiation is accompanied by differential splicing of \hat{l}^2 -amyloid precursor mRNAs in the PC12 cell line. Molecular Brain Research, 1991, 10, 351-354.	2.5	37
100	Antagonistic effects of dexamethasone and 1,25-dihydroxyvitamin D3 on the synthesis of nerve growth factor. Molecular and Cellular Endocrinology, 1991, 78, R1-R6.	1.6	22
101	MC903, an analogue of 1,25-dihydroxyvitamin D3, increases the synthesis of nerve growth factor. European Journal of Pharmacology, 1991, 208, 189-191.	2.7	13
102	1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. Journal of Neuroscience Research, 1991, 28, 110-114.	1.3	196
103	Involvement of Protein Kinase C in the Regulation of Nerve Growth Factor Synthesis: A Possible Cause of Impaired Trophic Supply in Alzheimer's Disease?. , 1991, , 73-80.		0
104	Phorbol 12-myristate 13-acetate (PMA) increases the expression of the nerve growth factor (NGF) gene in mouse L-929 fibroblasts. FEBS Letters, 1990, 262, 42-44.	1.3	44
105	Levels of nerve growth factor secreted by rat primary fibroblasts and iris transplants are influenced by serum and glucocorticoids. Developmental Brain Research, 1989, 47, 171-179.	2.1	34
106	Serum contains a macromolecular effector promoting the synthesis of Nerve Growth Factor (NGF) in L cells. Biochemical and Biophysical Research Communications, 1988, 150, 723-730.	1.0	13
107	Partial sequence of the rat heavy neurofilament polypeptide (NF-H) Identification of putative phosphorylation sites. FEBS Letters, 1988, 241, 213-218.	1.3	18
108	Messenger RNAs of βâ€amyloid precursor protein and prion protein are regulated by nerve growth factor in PC12 cells. International Journal of Developmental Neuroscience, 1988, 6, 387-389.	0.7	49

#	Article	IF	CITATIONS
109	Retinoic acid increases the expression of NGF gene in mouse L cells. Biochemical and Biophysical Research Communications, 1987, 149, 510-514.	1.0	35
110	Isolation of a cDNA for the rat heavy neurofilament polypeptide (NF-H). FEBS Letters, 1986, 209, 203-205.	1.3	50
111	Molecular cloning of the avian \hat{l}^2 -nerve growth factor gene: transcription in brain. FEBS Letters, 1986, 203, 82-86.	1.3	37
112	Dexamethasone rapidly reduces the expression of the \hat{l}^2 -NGF gene in mouse L-929 cells. Experimental Cell Research, 1986, 162, 562-565.	1.2	50
113	Serum Influences β-NGF Gene Expression in Mouse L Cells. Proceedings in Life Sciences, 1986, , 40-42.	0.5	3
114	Serum and thyroid hormones T3 and T4 regulate nerve growth factor mRNA levels in mouse L cells. FEBS Letters, 1985, 189, 37-41.	1.3	51
115	Synthesis and partial maturation of the \hat{l}_{\pm} - and \hat{l}_{3} -subunits of the mouse submaxillary gland nerve growth factor inXenopus laevisoocytes. FEBS Letters, 1984, 166, 104-108.	1.3	11